(0.03%) 5 538.75 points
(-0.12%) 39 480 points
(0.15%) 20 003 points
(0.83%) $81.50
(-2.25%) $2.69
(-0.47%) $2 319.90
(0.11%) $28.90
(1.09%) $997.20
(0.29%) $0.936
(0.36%) $10.64
(0.26%) $0.790
(-0.27%) $87.25
2.68% $ 1.150
Live Chart Being Loaded With Signals
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases...
Stats | |
---|---|
Объем за сегодня | 714 184 |
Средний объем | 185 179 |
Рыночная капитализация | 47.77M |
EPS | $-0.460 ( Q1 | 2024-05-09 ) |
Дата следующего отчета о доходах | ( $-0.360 ) 2024-08-08 |
Last Dividend | $0.361 ( 2023-03-08 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.030 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-17 | Morris Richard Steven | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Klichinsky Michael | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Kelly Steven | Buy | 125 000 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 38 700 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 0 |
INSIDER POWER |
---|
100.00 |
Last 7 transactions |
Buy: 1 112 700 | Sell: 0 |
Объем Корреляция
Carisma Therapeutics, Корреляция
10 Самые положительные корреляции | |
---|---|
OZEM | 1 |
BNZI | 0.962 |
LUXH | 0.96 |
AAME | 0.942 |
CHUY | 0.936 |
FRGT | 0.934 |
AMPL | 0.933 |
HPKEW | 0.933 |
DYFI | 0.932 |
AEON | 0.931 |
10 Самые отрицательные корреляции | |
---|---|
JAJWX | -0.955 |
DTI | -0.944 |
ATMV | -0.94 |
CNRLX | -0.94 |
NEOV | -0.928 |
OCMAX | -0.928 |
IROH | -0.925 |
FORL | -0.922 |
QTTB | -0.92 |
ISRL | -0.919 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Carisma Therapeutics, Корреляция - Валюта/Сырье
Carisma Therapeutics, Финансовые показатели
Annual | 2023 |
Выручка: | $14.92M |
Валовая прибыль: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2023 |
Выручка: | $14.92M |
Валовая прибыль: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2022 |
Выручка: | $9.83M |
Валовая прибыль: | $3.74M (38.07 %) |
EPS: | $-575.42 |
Financial Reports:
No articles found.
Carisma Therapeutics, Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.361 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.361 | 2023-03-08 |
Last Dividend | $0.361 | 2023-03-08 |
Next Dividend | $0 | N/A |
Payout Date | 2023-03-08 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.361 | -- |
Avg. Dividend % Per Year | 0.94% | -- |
Score | 0.39 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.361 | 2.82% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
08 Mar 2023 | $0.361 | 03 Feb 2023 | 07 Mar 2023 | 08 Mar 2023 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -5.39 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.101 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.16 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.42 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.30 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.102 | -1.500 | 8.31 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -103.61 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.968 | -1.935 | [0 - 20] |
debtEquityRatioTTM | 0.688 | -1.500 | 7.25 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.656 | 1.000 | 2.40 | 2.40 | [0.2 - 0.8] |
operatingProfitMarginTTM | -5.66 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -10.44 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.204 | 0.800 | -1.972 | -1.577 | [0.5 - 2] |
Total Score | -1.801 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.580 | 1.000 | -0.160 | 0 | [1 - 100] |
returnOnEquityTTM | -2.16 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.645 | -1.935 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0261 | 1.500 | -3.51 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -5.19 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.80 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Carisma Therapeutics,
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа